The analyses and visuals on this site are for informational purposes only and do not constitute investment advice.

© 2026 Datafin Financial Data Analysis Systems. All rights reserved. · v2.0

Privacy PolicyTerms of UseCookie Policy

AVIR FINANCIAL STATEMENTS

Atea Pharmaceuticals Inc — balance sheet, income statement and cash flow trends

AVIRAtea Pharmaceuticals Inc

🇺🇸 USA · NASDAQ · Healthcare · Biotechnology

Value itDuel
PriceFinancialsPeers

Income Statement

Quarterly progression — trailing-twelve-month values
RevenueNet Income to Owners
-200 M0200 M202120222023202420252026

Profit Funnel

Q2 2026 · TTM
Revenue0 $Gross Profit-38.4 M $ · -Infinity%Operating Income-183.6 M $ · -Infinity%Pre-tax Income-171.8 M $ · -Infinity%Net Income to Owners-165.3 M $ · -Infinity%

Percentages are relative to revenue.

Key Figures

YoY change
Revenue0 $-100.0%
Gross Profit-38.4 M $—
Operating Income-183.6 M $—
EBITDA-171.3 M $—
Net Income to Owners-165.3 M $—

No peer data is available for this stock.

Balance Sheet

Quarterly period-end values
Total AssetsTotal LiabilitiesEquity
0250 M500 M750 M202120222023202420252026

Capital Structure

Q2 2026
Total Assets232.3 M
  • Equity204.2 M $88%
  • Current Liabilities28.1 M $12%

Key Figures

YoY change
Total Assets232.3 M $-40.7%
Total Liabilities28.1 M $+3.4%
Total Equity204.2 M $-44.0%
Cash & ST Investments219.5 M $-42.2%
Total Debt424 K $-66.0%
Net Debt-76.1 M $—

No peer data is available for this stock.

Cash Flow Statement

Quarterly progression — trailing-twelve-month values
Operating Cash FlowCapital ExpendituresFree Cash Flow
-200 M0200 M202120222023202420252026

Cash Flow Bridge

Q2 2026 · TTM
-150 M-100 M-50 M0-152.1 M $Operating151.9 M $Investing-11 M $Financing-11.2 M $Net Change

Key Figures

YoY change
Operating Cash Flow-152.1 M $—
Capital Expenditures0 $—
Free Cash Flow-152.1 M $—
Dividends Paid——

No peer data is available for this stock.

Amounts are in the company’s reporting currency. Peer comparison tables use ratio-based metrics so currency differences do not distort the picture.

Go deeper on AVIR

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Sep 11, 26. This content is for informational purposes only and is not investment advice.